Skip to content
Search

Latest Stories

Labour MP Darren Jones visits Sigma’s Watford site on campaign trail

Labour MP Darren Jones visits Sigma’s Watford site on campaign trail

The Labour Party pledges to support community pharmacies and release much-needed resources if it comes to power

Darren Jones MP, the Shadow Chief Secretary to the Treasury, visited Sigma Pharmaceuticals plc‘s new Watford facility on Thursday (6 June) as part of the Labour Party general election campaign.


Jones was joined by Labour’s prospective parliamentary candidate for Watford, Matt Turmaine, and a team of campaign workers.

During their visit, the Labour delegation met with the directors and founding member of Sigma, Dr Bharat Shah CBE, and discussed the importance of investment and support for growing businesses and the pharmaceutical sector both in the region and across the country.

Sigma Pharmaceuticals, which is believed to be Watford’s largest employer, noted that the pharmaceutical sector contributes a significant value to the East of England, accounting for 12.3 per cent of the region’s manufacturing gross value added (GVA).

The discussion also covered generic medicines, which help save the NHS billions of pounds over the years, as well as policy and the financial challenges currently facing the pharmaceutical industry.

Impressed by Sigma’s operations, Jones expressed Labour’s commitment to supporting community pharmacy and exploring more innovative ways of adding value to the high street pharmacy in Britain.

“We were very impressed with what Sigma has achieved for community pharmacy in the UK and were quite taken aback by the sheer size and scale of their Watford operation.

“It is a Labour party pledge to support community pharmacy and to strive for a better way of sustaining government help and releasing much-needed resources for this all-important part of the nation’s health and wellbeing,” he said.

Dr Shah welcomed the Labour team’s visit, expressing hope for better policies for local pharmacies from the next government.

He said: “It was great to have Darren, Matt and the Labour Party team pay a timely visit to our business. It is our hope that the new government will be proactive and implement serious policy decisions to meet the needs of local pharmacy and appreciate the vital role they play in the health of our nation.”

Group CEO Hatul Shah asked the Labour team numerous pertinent questions about policy and the proposed actions the party plans to implement if they come into power after the 4th of July.

Sigma’s Commercial Director, Raj Haria, demonstrated the day-to-day activities of the company and highlighted the current financial impact felt within the pharmaceutical industry.

Jones  and his team were given an extensive tour of Sigma’s new Watford facility, and witnessed the company’s advanced processes for handling, packing, and delivering medications prescribed by doctors.

Sigma highlighted that their fleet of temperature-controlled vehicles is crucial to meeting daily demands without fail.

Watford is a marginal seat, and the Labour visit is aimed at rallying local support for its prospective candidate in the constituency.

 

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less